Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Conditions: NSCLC Stage IV; Brain Metastases, Adult Interventions: Drug: Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab Sponsors: Maastricht University Medical Center; Gilead Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials